0001610717-23-000217.txt : 20230721
0001610717-23-000217.hdr.sgml : 20230721
20230721210601
ACCESSION NUMBER: 0001610717-23-000217
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230720
FILED AS OF DATE: 20230721
DATE AS OF CHANGE: 20230721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martell Bridget A
CENTRAL INDEX KEY: 0001629627
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 231103590
MAIL ADDRESS:
STREET 1: C/O POINT BIOPHARMA GLOBAL INC.
STREET 2: 4850 WEST 78TH STREET
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46268
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2023-07-20
0001799448
Aligos Therapeutics, Inc.
ALGS
0001629627
Martell Bridget A
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
false
Stock Option (Right to Buy)
1
2023-07-20
4
A
0
20000
0
A
2033-07-20
Common Stock
20000
20000
D
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
/s/ Lucinda Y. Quan, as attorney-in fact for Bridget Martell
2023-07-21